Further according to the present disclosure, there are methods for promoting egg maturation in assisted reproductive technologies, such as inin vitrofertilization (IVF) or in an embryo transfer (ET) process. There are also methods for decreasing the rate of ovarian hyper-stimulation syndrome (OHSS), providing comparable or improved pregnancy rates, decreasing the time to pregnancy, and inhibiting premature ovulation. The methods include the step of administering a therapeutically effective amount of an active pharmaceutical ingredient of 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl- L-phenylalanyl)hydrazinocarbonyl-L-leucyl-Nω-methyl-L-arginyl-L-tryptophanamide or a pharmaceutically acceptable salt thereof.本發明進一步係關於諸如活體外授精(IVF)或胚胎轉移(ET)方法之輔助生殖技術中促進卵成熟之方法。亦有降低卵巢過度刺激症候群(OHSS)比率、提供相當或改良之受孕率、縮短受孕時間及抑制過早排卵之方法。該等方法包括投與治療有效量之活性醫藥成分2-(N-乙醯基-D-酪胺醯基-反式-4-羥基-L-脯胺醯基-L-天冬醯胺醯基-L-羥丁胺醯基-L-苯丙胺醯基)肼基羰基-L-白胺醯基-Nω-甲基-L-精胺醯基-L-色胺酸醯胺或其醫藥學上可接受之鹽之步驟。
